← Back to patent-cliff list
Privosegtor
Tier C — Watch / tradePrivosegtor
Accure Therapeutics SL
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：SGK2, IGF1, BDNF
Indications (approved)：视神经炎, Demyelinating disease, Actinic keratosis
Regional status
US
Phase III
2026-05-28
EU
Phase II
2021-02-10
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Privosegtor?
Approved indications include: 视神经炎, Demyelinating disease, Actinic keratosis.
When does the Privosegtor patent expire?
No public expiry year is available for Privosegtor yet; this page updates once verified.
How do I get a quote for Privosegtor intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29